PATENT CLAIM ANALYSIS

Application Number: 15945011
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "138100"]

Abstract:
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Claim (Index 8):
A mammalian cell comprising a first DNA molecule and a second DNA molecule, wherein the first DNA molecule comprises a polynucleotide sequence encoding polypeptides having the amino acid sequence of SEQ ID NO: 11 and SEQ ID NO: 12, and wherein the second DNA molecule comprises a polynucleotide sequence encoding polypeptides having the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 18, wherein the cell is capable of expressing the antibody of  claim 6 .

Metadata:
- Claim Count in Document: 3.0
- Percentile: 91.0
- Lexical Diversity: 1.2069
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15239959', '15232026', '16064727', '15005042', '14709514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7692425038999949
- 35 USC 102 Novelty (BERT): 0.5224121571891371
- Combined Prediction Score: 0.7445594692289091
- Mean Citation Score: 328.78834399999994
- Max Citation Score: 344.3392
- Similarity Product: 283.43560128860474

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test